APA

Valantin M. A., Bittar R., de Truchis P., Bollens D., Slama L., Giral P., Bonnefont-Rousselot D., Pétour P., Aubron-Olivier C., Costagliola D. & Katlama C. (20100421). Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. : The Journal of antimicrobial chemotherapy.

Chicago

Valantin M A, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, Bonnefont-Rousselot D, Pétour P, Aubron-Olivier C, Costagliola D and Katlama C. 20100421. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. : The Journal of antimicrobial chemotherapy.

Harvard

Valantin M. A., Bittar R., de Truchis P., Bollens D., Slama L., Giral P., Bonnefont-Rousselot D., Pétour P., Aubron-Olivier C., Costagliola D. and Katlama C. (20100421). Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. : The Journal of antimicrobial chemotherapy.

MLA

Valantin M A, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, Bonnefont-Rousselot D, Pétour P, Aubron-Olivier C, Costagliola D and Katlama C. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. : The Journal of antimicrobial chemotherapy. 20100421.